In accordance, HIF-2α blockade improves YTHDF2-mediated suppression on m6A-mRNA stability and inflammatory cancer behaviors, leveraging this metabolic-epigenetic axis toward therapeutic opportunities in human HCC. Here, YTHDF2 is linked to hepatocellular carcinoma.